« Return to News | CROs/Service Providers

BMS acquires Amira for $325 million

Monday, July 25, 2011 10:11 AM

Bristol-Myers Squibb will acquire privately-held Amira Pharmaceuticals, a small-molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.

BMs will acquire all of Amira’s issued and outstanding shares of capital stock and stock equivalents in an all-cash transaction for $325 million upfront and potential additional milestone payments totaling $150 million. BMS will secure Amira’s fibrosis program, including lead asset AM152, an orally available lysophosphatidic acid 1 (LPA1) receptor antagonist that has completed phase I clinical studies and is poised for phase IIa proof-of-confidence studies for the treatment of idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (SSc), or scleroderma.

BMs will also obtain Amira’s pre-clinical autotaxin program, which may be useful in the treatment of neuropathic pain and cancer metastases. BMS plans to retain Amira scientists who work on both of these programs, and they will remain in San Diego.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.